213 related articles for article (PubMed ID: 11669548)
1. The role of somatostatin and octreotide in bowel obstruction: pre-clinical and clinical results.
Ripamonti C; Panzeri C; Groff L; Galeazzi G; Boffi R
Tumori; 2001; 87(1):1-9. PubMed ID: 11669548
[TBL] [Abstract][Full Text] [Related]
2. Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double- blind, controlled clinical trial.
Mystakidou K; Tsilika E; Kalaidopoulou O; Chondros K; Georgaki S; Papadimitriou L
Anticancer Res; 2002; 22(2B):1187-92. PubMed ID: 12168923
[TBL] [Abstract][Full Text] [Related]
3. Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction.
Hisanaga T; Shinjo T; Morita T; Nakajima N; Ikenaga M; Tanimizu M; Kizawa Y; Maeno T; Shima Y; Hyodo I
Jpn J Clin Oncol; 2010 Aug; 40(8):739-45. PubMed ID: 20410056
[TBL] [Abstract][Full Text] [Related]
4. Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer.
Peng X; Wang P; Li S; Zhang G; Hu S
World J Surg Oncol; 2015 Feb; 13():50. PubMed ID: 25889313
[TBL] [Abstract][Full Text] [Related]
5. [A clinical study using octreotide in relieving gastrointestinal symptoms due to bowel obstruction in a terminally ill cancer patient].
Shima Y; Yamaguchi K; Miyata Y; Hyodo I; Yagi Y; Honke Y
Gan To Kagaku Ryoho; 2004 Sep; 31(9):1377-82. PubMed ID: 15446560
[TBL] [Abstract][Full Text] [Related]
6. Palliation of malignant intestinal obstruction using octreotide.
Khoo D; Hall E; Motson R; Riley J; Denman K; Waxman J
Eur J Cancer; 1994; 30A(1):28-30. PubMed ID: 7511400
[TBL] [Abstract][Full Text] [Related]
7. A prospective study on the efficacy of octreotide in the management of malignant bowel obstruction in gynecologic cancer.
Watari H; Hosaka M; Wakui Y; Nomura E; Hareyama H; Tanuma F; Hattori R; Azuma M; Kato H; Takeda N; Ariga S; Sakuragi N
Int J Gynecol Cancer; 2012 May; 22(4):692-6. PubMed ID: 22343971
[TBL] [Abstract][Full Text] [Related]
8. Medical management of malignant bowel obstruction in patients with advanced cancer: 2021 MASCC guideline update.
Davis M; Hui D; Davies A; Ripamonti C; Capela A; DeFeo G; Del Fabbro E; Bruera E
Support Care Cancer; 2021 Dec; 29(12):8089-8096. PubMed ID: 34390398
[TBL] [Abstract][Full Text] [Related]
9. Octreotide for long-lasting malignant bowel obstruction: two case reports.
Mercadante S; Tartaglia L
Ann Palliat Med; 2024 Jan; 13(1):183-186. PubMed ID: 38316401
[TBL] [Abstract][Full Text] [Related]
10. Octreotide in the management of bowel obstruction in terminal ovarian cancer.
Mangili G; Franchi M; Mariani A; Zanaboni F; Rabaiotti E; Frigerio L; Bolis PF; Ferrari A
Gynecol Oncol; 1996 Jun; 61(3):345-8. PubMed ID: 8641613
[TBL] [Abstract][Full Text] [Related]
11. Octreotide in malignant intestinal obstruction.
Pandha HS; Waxman J
Anticancer Drugs; 1996 Jan; 7 Suppl 1():5-10. PubMed ID: 8822079
[TBL] [Abstract][Full Text] [Related]
12. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction.
Mercadante S; Ripamonti C; Casuccio A; Zecca E; Groff L
Support Care Cancer; 2000 May; 8(3):188-91. PubMed ID: 10789958
[TBL] [Abstract][Full Text] [Related]
13. Antisecretory agents in gastrointestinal obstruction.
Muir JC; von Gunten CF
Clin Geriatr Med; 2000 May; 16(2):327-34. PubMed ID: 10783431
[TBL] [Abstract][Full Text] [Related]
14. Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial.
Ripamonti C; Mercadante S; Groff L; Zecca E; De Conno F; Casuccio A
J Pain Symptom Manage; 2000 Jan; 19(1):23-34. PubMed ID: 10687323
[TBL] [Abstract][Full Text] [Related]
15. Octreotide in relieving gastrointestinal symptoms due to bowel obstruction.
Mercadante S; Spoldi E; Caraceni A; Maddaloni S; Simonetti MT
Palliat Med; 1993; 7(4):295-9. PubMed ID: 7505187
[TBL] [Abstract][Full Text] [Related]
16. Scopolamine butylbromide plus octreotide in unresponsive bowel obstruction.
Mercadante S
J Pain Symptom Manage; 1998 Nov; 16(5):278-80. PubMed ID: 9846021
[No Abstract] [Full Text] [Related]
17. Clinical impact of palliative treatment using octreotide for inoperable malignant bowel obstruction caused by advanced urological cancer.
Kubota H; Taguchi K; Kobayashi D; Naruyama H; Hirose M; Fukuta K; Kubota Y; Yasui T; Yamada Y; Kohri K
Asian Pac J Cancer Prev; 2013; 14(12):7107-10. PubMed ID: 24460259
[TBL] [Abstract][Full Text] [Related]
18. Pathophysiology and palliation of inoperable bowel obstruction in patients with ovarian cancer.
Jatoi A; Podratz KC; Gill P; Hartmann LC
J Support Oncol; 2004; 2(4):323-34; discussion 334-7. PubMed ID: 15357517
[TBL] [Abstract][Full Text] [Related]
19. Malignant irreversible intestinal obstruction: the powerful association of octreotide to corticosteroids, antiemetics, and analgesics.
Weber C; Zulian GB
Am J Hosp Palliat Care; 2009; 26(2):84-8. PubMed ID: 19088264
[TBL] [Abstract][Full Text] [Related]
20. Management of malignant bowel obstruction.
Ripamonti CI; Easson AM; Gerdes H
Eur J Cancer; 2008 May; 44(8):1105-15. PubMed ID: 18359221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
